Zelira Enters Deal to Develop Products For Vascular Diseases
Filed with ASX · · 6 pages · English
Teleconference at 11am (AEST) Thursday 23 July Conference ID: 10008777. Pre‐registration: https://s1.c‐conf.com/diamondpass/10008777‐invite.html Dial‐in (toll free) Australia: 1800 455 963 (For more dial in options see the bottom of the release) Zelira enters into a commercial agreement to develop products targeting symptoms associated with Peripheral Arterial Disease and Diabetic Neuropathies 22
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints
- TasAlk to Manufacture Zeliras Insomnia and HOPE products
- March 2020 Quarterly Report
- Insomnia Trial Meets Primary and Secondary Endpoints
- Appendix 4D & FY20 Interim Financial Report
Later from Zelira Therapeutics
- June 2020 Quarterly Report
- ZLD Successfully Completes $8.75M Oversubscribed Placement
- HOPE Range Of Products Launches In Louisiana
- Appendix 4E & Financial Statements
- Zelira Forms Subsidiary to Launch Oral Care Products in USA
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics